Skip to main content

Table 2 Baseline characteristic of patients

From: A novel citrate-based protocol versus heparin anticoagulation for sustained low-efficiency dialysis in the ICU: safety, efficacy, and cost

Characteristic

All

Citrate

Heparin

Both

p

Patients

282

75 (27%)

79 (28%)

128 (45%)

 

Age

68 ± 13

67 ± 12

69 ± 14

69 ± 14

0.25

Dialysis per patientb

6 ± 7

4 ± 4

4 ± 4

9 ± 9

< 0.001

Female

101 (36%)

28 (37%)

30 (38%)

43 (34%)

0.89

Race

 White

256 (91%)

68 (91%)

73 (92%)

115 (90%)

0.99

 Asian

5 (2%)

3 (4%)

0

2 (2%)

 

 Arab

20 (7%)

4 (5%)

0

10 (7%)

 

 Black

1 (0,3%)

0

6 (8%)

1 (1%)

 

Sepsis

122 (43%)

26 (35%)

34 (43%)

62 (48%)

0.36

Liver cirrhosis

18 (6%)

9 (12%)

3 (4%)

6 (5%)

0.07

ARF

227 (80%)

60 (80%)

71 (90%)

96 (75%)

0.49

 Anuria/oliguria

153 (67%)

37 (62%)

45 (63%)

71 (74%)

0.51

MOF

19 (25%)

32 (33%)

24 (30%)

50 (39%)

0.54

Invasive mechanical ventilation

213 (76%)

51 (68%)

54 (68%)

108 (84%)

0.31

Needs of catecholamine

202 (72%)

50 (67%)

51 (65%)

101 (79%)

0.44

Time of hospitalization (day)a

18 (8-32)

14 (4-29)

14 (6-26)

22 (11-40)

< 0.001

SAPS II score

44 ± 14

45 ± 14

42 ± 13

44 ± 14

0.504

In-hospital mortality

138 (49%)

34 (45%)

34 (43%)

70 (55%)

0.42

  1. Continuous variables are present as mean ± SD or median (Interquartile range: Q1-Q3)
  2. a Categorical variables are present as frequency (n) and percentage (%)
  3. b Significant difference among groups. No significant difference between group Citrate and group Heparin